ASCLF (Ascletis Pharma) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 13, 2026)


ASCLF Ascletis Pharma Inc ASCLF
38 GF Score
Price $1.44
GF Value $0.02
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ascletis Pharma Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Ascletis Pharma's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

ASCLF vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Ascletis Pharma's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascletis Pharma Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascletis Pharma's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Ascletis Pharma's Margin of Safety % (DCF Earnings Based) falls into.


ASCLF
38GF Score
Ascletis Pharma Inc ASCLF
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ascletis Pharma (ASCLF) Overvalued in 2026?

Based on GuruFocus' analysis, Ascletis Pharma stock appears to be overvalued. The current stock price of $1.44 is trading 7100% above its estimated GF Value™ of $0.02. GuruFocus considers Ascletis Pharma to be Significantly Overvalued.

Key valuation signals for ASCLF:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $0.02 vs. price of $1.44 (7100% above fair value)
  • GF Score™: 38/100 with 5 warning signs

No single metric tells the full story. See the ASCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ascletis Pharma Business Description

Other Exchanges 01672:Hong Kong2VJ:Germany
Address No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Wanchai, HKG, 311200
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
38GF Score

Get the complete analysis for ASCLF

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.44
Price
$0.02
GF Value